European Commission Approves Pfizer’s LITFULO for Adolescents and Adults With Severe Alopecia Areata
Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for LITFULO (ritlecitinib) to treat adults and adolescents 12 years of age and older with…
Read More...
Read More...
